Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct 13;8(10):e11081.
doi: 10.1016/j.heliyon.2022.e11081. eCollection 2022 Oct.

Cell cycle associated miRNAs as target and therapeutics in lung cancer treatment

Atqiya Fariha  1 , Ithmam Hami  1 , Mahafujul Islam Quadery Tonmoy  1 , Shahana Akter  1 , Hasan Al Reza  2 , Newaz Mohammed Bahadur  3 , Md Mizanur Rahaman  4 , Md Shahadat Hossain  1
Affiliations
Review

Cell cycle associated miRNAs as target and therapeutics in lung cancer treatment

Atqiya Fariha et al. Heliyon. .

Abstract

Lung cancer is the primary cause of cancer related deaths worldwide. Limited therapeutic options and resistance to existing drugs are the major hindrances to the clinical success of this cancer. In the past decade, several studies showed the role of microRNA (miRNA) driven cell cycle regulation in lung cancer progression. Therefore, these small nucleotide molecules could be utilized as promising tools in lung cancer therapy. In this review, we highlighted the recent advancements in lung cancer therapy using cell cycle linked miRNAs. By highlighting the roles of the specific cell cycle core regulators affiliated miRNAs in lung cancer, we further outlined how these miRNAs can be explored in early diagnosis and treatment strategies to prevent lung cancer. With the provided information from our review, more medical efforts can ensure a potential breakthrough in miRNA-based lung cancer therapy.

Keywords: Biomarker; Cancer therapy; Cell cycle; NSCLC; miRNA.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Timeline of miRNAs in Lung Cancer Research.
Figure 2
Figure 2
The Role of miRNA in lung cancer formation.
Figure 3
Figure 3
(a) Therapeutic potentiality of miRNA in lung cancer treatment from target identification to treatment approach. (b) Diagrammatic representation of therapeutic mode of action of miRNAs within the cell structure during miRNA inhibition therapy and miRNA replacement therapy.
See this image and copyright information in PMC

References

    1. Sung H., et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca - Cancer J. Clin. 2021;71(3):209–249. - PubMed
    1. Brunelli A., et al. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: diagnosis and management of lung cancer: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5):e166S–e190S. - PubMed
    1. Mariotto A.B., et al. Projections of the cost of cancer care in the United States: 2010–2020. J. Natl. Cancer Inst. 2011;103(2):117–128. - PMC - PubMed
    1. Hasan N., Kumar R., Kavuru M.S. Lung cancer screening beyond low-dose computed tomography: the role of novel biomarkers. Lung. 2014;192(5):639–648. - PubMed
    1. Zhao Z., et al. MicroRNA-25 regulates small cell lung cancer cell development and cell cycle through cyclin E2. Int. J. Clin. Exp. Pathol. 2014;7(11):7726. - PMC - PubMed

LinkOut - more resources